CXCL9 and metabolic dysfunction-associated steatotic liver disease: A microarray dataset analysis of published data containing samples from 24 healthy, 20 NAFLD, and 19 NASH patients (GEO: GSE89632 [147]) by Xiong et al., showed that, similar to the NASH mouse, during human NASH pathogenesis there is a hepatic transcript abundance of CXCL9 and FABP4, while the expression of BMP2, NRP1, and VEGFA is reduced in the hepatic tissues of patients with NAFLD and NASH [146].